OBJECTIVE: To explore the effect of toxicity of sunitinib on the clinical outcome of patients with advanced renal cell carcinoma (RCC).
METHODS: A total of 136 patients with advanced RCC were treated with sunitinib from 2008 to 2011. There were 91 males and 45 females with an average age of 56 years. Their 6-week therapy cycle was 4 weeks of sunitinib 50 mg daily followed by 2-week off-treatment (schedule 4/2). The median follow-up time was 15 months. Correlation between toxicities and overall survival (OS) was evaluated in a Cox model using log-transformed levels after adjusting for MSKCC model. Log-rank test and Cox proportional hazard model were used to assess the value of drug toxicity as the prognostic factors.
RESULTS: The increased hemoglobin on cycle 1 day 14 (HR:0.950, 95%CI:0.923-0.978) and the increased lymphocytes on cycle 1 days 28 and 42 (HR:0.405, 95%CI:0.203-0.809, HR:0.394, 95%CI:0.179-0.867) were significantly associated with OS (P adj = 0.001, 0.014 and 0.022 respectively). Hypertension class III/IV (HR:0.066, 95%CI:0.008-0.582), and the number of neutrophils screening and lymphocyte count ratio (HR:2.537, 95%CI:1.182-5.404) were the survival prognosis independent predictors.
CONCLUSION: Early hematopoietic toxicities may potentially predict the outcomes of advanced RCC after a therapy of sunitinib.
Written by:
Hong YP, Yao XD, Zhu Y, Ye DW, Shi GH, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu YP, Ma CG, Xiao WJ, Qin XJ, Lin GW. Are you the author?
Department of Urology, Fudan University Cancer Hospital, Shanghai 200032, China; Department of Urology, No.10 People's Hospital of Tongji University, Shanghai 200072, China.
Reference: Zhonghua Yi Xue Za Zhi. 2013 Sep 24;93(36):2880-3.
PubMed Abstract
PMID: 24373400
Article in Chinese.
UroToday.com Renal Cancer Section
